Product Information |
Product name |
Loxoprofen sodium; Loxoprofen sodium hydrate |
CAS No. |
80382-23-6 |
Molecular Formula |
C15H17NaO3 |
Molecular Weight |
268.288 |
Molecular Structure |
|
Quality Standard |
98.5% up by HPLC |
Appearance |
White to yellowish white crystalline powder |
COA |
ANALYSIS |
SPECIFICATION |
RESULTS |
Appearance |
White to yellowish white crystalline powder |
White crystalline powder |
Characters |
Very soluble in water and in methanol, freely soluble in ethanol and practically insoluble in diethyl ether. |
Complied |
Optical rotation |
No optical rotation |
Complied |
pH |
6.5-8.5 |
.7.7 |
Identification |
UV-VIS: UV absorptionspectrum of this product should be complied with that of reference spectrum in JP(UV1102) |
Complied |
IR: IR absorption spectrum of this product should be complied with that of reference spectrum in JP(IR1102) |
Complied |
|
Sodium (Na+): Positive |
Positive |
|
Clarity and color |
The solution is clear and colorless or pale yellow. The color is not darker than that of diluted Matching Fluid A(1 in 2) |
The solution is clear and the color is not darker than that of diluted Matching Fluid A (1 in 2) |
Related substance |
TLC: the spots other than the principal spot from the sample solution are not more intense than the spot from the standard solution. |
Complied |
Impurity A ≤ 0.15% |
0.01% |
|
Impurity B ≤ 0.15% |
0.05% |
|
Impurity D ≤ 0.15% |
0.005% |
|
Other single impurity ≤ 0.10% |
0.03% max |
|
Total impurities ≤ 0.50% |
0.12% |
|
Residual solvent |
Acetone ≤ 0.50% |
0.01% |
Water |
11% - 13% |
11.7% |
Heavy metals |
≤ 10ppm |
< 10ppm |
Assay |
Calculated on the anhydrous basis, contains 98.5%-101.0% of C15H17NaO3 |
99.9% |
Conclusion |
The product meets the specification |
Usage |
What is Loxoprofen sodium?
Loxoprofen sodium, an anti-inflammatory prodrug (NSAID), is a nonselective COX inhibitor with IC50s of 6.5 and 13.5μM for COX-1 and COX-2 in human whole blood assays, respectively.
Loxoprofen (LOX) sodium is a non-selective cyclooxygenase inhibitor that is widely used for the reasearch of pain and inflammation caused by chronic and transitory conditions. Its alcoholic metabolites are formed by carbonyl reductase (CR) and they consist of trans-LOX, which is active, and cis-LOX, which is inactive. In addition, LOX sodium can also be converted into an inactive hydroxylated metabolite (OH-LOXs) by cytochrome P450 (CYP).
*Products under the patent are only for R&D use